June 202617
A systematic review found sexual side effects of 5α-reductase inhibitors infrequent and mostly reversible, though susceptibility varies and long-term persistence data are lacking. A review found tretinoin-minoxidil co-therapy poorly supported first-line, though it reportedly converts some minoxidil nonresponders at the cost of irritation. A review of emerging androgenetic alopecia drugs covered clascoterone, GT20029, HMI-115 and PP405, with trials still defining their roles. A review found botulinum toxin A injections associated with increased hair growth, alone or alongside finasteride and minoxidil. A review of non-surgical hair restoration stressed accurate diagnosis and combination therapy across pharmacologics, PRP and microneedling.
- Sexual dysfunction associated with 5α-reductase inhibitors in the treatment of androgenetic alopecia: a systematic review A systematic review found sexual side effects infrequent on finasteride (1.9-6.7% vs 0.9-3.9% placebo) and dutasteride, mostly mild and reversible, though individual susceptibility varies and long-term persistence data are lacking.
- Efficacy of Topical Tretinoin and Topical Minoxidil Cotherapy in Androgenetic Alopecia: A Review A review found little clinical support for tretinoin-minoxidil co-therapy first-line, though it may convert some minoxidil nonresponders to responders, at the cost of irritation.
- Emerging pharmacotherapies for androgenetic alopecia A review surveys emerging androgenetic alopecia drugs including clascoterone, GT20029, HMI-115, PP405 and improved minoxidil delivery, with clinical trials still to define their roles.
- Treatment Response to JAK Inhibitors in Long-standing Alopecia Areata (≥8 Years): A Real-world Observational Study In 31 patients with alopecia areata episodes lasting over 8 years, 27.6% reached SALT scores of 20 or less on JAK inhibitors; most discontinued, mainly for lack of efficacy.
- Efficacy and tolerability of scalp cooling in preventing alopecia during (neo)adjuvant chemotherapy for breast cancer Scalp cooling prevented severe chemotherapy-induced alopecia in 69% of breast cancer patients on anthracycline-free regimens but only 37.5% on anthracyclines; most found it tolerable.
- Botulinum toxin A for the Treatment of Androgenetic Alopecia: A Review A review of six studies found botulinum toxin A injections associated with increased hair growth in androgenetic alopecia, alone or with finasteride and minoxidil, with a favorable safety profile.
- A Pilot Randomized Controlled Trial Comparing the Efficacy and Safety of Oral Tofacitinib Versus Methotrexate In Moderate-to-Severe Alopecia Areata A pilot RCT of 36 patients found SALT 20 or less achieved by 50% on tofacitinib versus 33% on methotrexate, a non-significant difference, with similar adverse events.
- Alopecia areata: current concepts A review of alopecia areata highlights immune privilege collapse and JAK-STAT activation as key mechanisms, with baricitinib and ritlecitinib now FDA-approved for severe disease.
- Non-Surgical Hair Restoration Options: Current Techniques and Emerging Technologies in Prejuvenation A review of non-surgical hair restoration covers pharmacologics, PRP, microneedling, lasers and emerging exosome and peptide therapies, stressing accurate diagnosis and combination therapy.
- Multimodal Human Scalp Atlas Defines Cell Landscape and Lineage Architecture In Situ A multimodal single-cell atlas of human scalp maps follicle cell states and distinct cellular programs in scarring versus non-scarring hair loss, as a research resource.
- Novel Combination Scalp Therapy for Androgenetic Alopecia: A Preliminary Retrospective Case Series with an Illustrative Four-Year Case An uncontrolled case series found a one-session combination procedure (surgery plus BTX, PRP, SVF injections) thickened hair shafts by a median 54% in six analyzable patients.
- Real-World Systemic Treatment Patterns and Outcomes of Children With Severe Alopecia Areata: A French Nationwide Study (ESTAPED Cohort) In 262 French children with severe alopecia areata, intravenous corticosteroids were the most-used first-line systemic; only 14.5% achieved remission five years after starting treatment.
- Uncertainty and Sensitivity Analysis of Hair Growth Duration in Human Scalp Follicles Under Normal and Alopecic Conditions A mathematical model of the hair cycle found greater uncertainty in growth-phase duration in androgenetic alopecia, with dermal papilla signaling highly influential on growth duration.
- Effectiveness of Botulinum Toxin Type A for Trichodynia Associated with Hair Loss Disorders: A Retrospective Study In 21 patients with trichodynia, intradermal botulinum toxin A reduced pain scores from 8.0 to 0.0 by 6 months, with stronger response in scarring alopecias.
- Long-term particulate matter exposure and risk of alopecia areata: a nationwide epidemiological study with preliminary in vitro evidence A nationwide Korean study linked long-term particulate matter exposure to higher incident alopecia areata risk (aHR 1.45 per 10 ug/m3 PM2.5), with in vitro inflammatory evidence.
- Patient Profile and Treatment Characteristics of Adults and Adolescents Prescribed Ritlecitinib for Alopecia Areata in the USA A US database study found ritlecitinib prescribed broadly in its first 10 months post-approval, including 35% adolescents and many treatment-naive alopecia areata patients.
- Development and validation of a comprehensive in vitro organ model for androgenetic alopecia A new human in vitro organ model of androgenetic alopecia replicates DHT-driven follicle miniaturization and its partial reversal by minoxidil or bicalutamide, as a drug-testing platform.